Intra-Cellular Therapies (“ITCI”) Stock Soars While Key Clinical Data Not Presented to Shareholders Looks Highly Disappointing

(July 15th, 2015) Biotech stocks have been on fire. And for good reason as numerous life-saving discoveries have come out of small, previously-unknown firms, making their owners rich many times over. But beneath the surface, a number of troubling drug development companies have caught the attention of investors with clinical data that’s dubious at best. With seemingly endless amounts of optimism, these biotech stocks have ridden the wave of investor enthusiam even when the data doesn’t look as promising as the market caps seem to indicate.

Read more

All You Ever Wanted to Know About Retrophin But Were Afraid to Ask

(June 2nd, 2014) Humans, like atoms, abhor unsteady states of existence. Just like electron transport gravitates towards a steady-state, people gravitate towards peaceful lands and away from battleground areas. Read more

Know What to Buy When Putin Comes Knocking

So Putin rolls a bunch of tanks up to the Ukrainian border and the market slides a percent or so. In any other market that would be considered a yawn. But here in the good ‘ol US of A, where the average active investor can barely remember the dog days of ’08, few traders seem to have the skill set necessary to maneuver in a down market. Having done this for 20+ years, I thought it would be helpful to share my trading tips for when war comes knocking.
Read more

IWB Acquisitions LLC Announces Expiration Date of Offer

Tuesday January 28, 8:05 am ET

NEW YORK, Jan. 28 /Businesswire/ — IWB Acquisitions LLC (“IWB”), a wholly-owned subsidiary of Zackfoot Investments LLC (“ZI”), announced today that its offer to acquire, Inc. (the “Company”) for $5.55 per common share expired at the close of business yesterday, as per the offer letter delivered to the Company’s Board of Directors on January 22nd , 2003.

Regarding the expiration, Mr. Prensky stated today: “We are disappointed that the Company did not respond to our offer, which they have had in their possession for over 5 days, since January 22nd. We believe that we gave them more than adequate time to respond to our offer. We made numerous phone calls to the Company and to individual Board members. Quite frankly, we are baffled as to why the Company did not contact us, particularly given the fact that, as a former member of the Company’s Board of Directors, I have had a longstanding interest in the domain name registration industry.”

Mr. Prensky also added, “We noted that an article that appeared in Crain’s New York Business on January 27th stated that the Company’s Board is hiring an investment banker. Should the circumstances warrant, we would be interested in re-engaging with the Company in the near future.”

It is currently not the intention of IWB and/or ZI to engage in any proxy solicitation. If IWB and/or ZI does engages in any solicitation with respect to the shares of it will prepare and disseminate a proxy statement with respect to that solicitation. Shareholders should read that proxy statement if and when it becomes available because it will contain important information. Shareholders will be able to obtain copies of the proxy statement, related materials and other materials filed with the Securities and Exchange Commission at the SEC’s website without charge when these documents become available. Shareholders will also be able to obtain copies of that proxy statement and related materials without charge, when available, from IWB by writing to: IWB Acquisitions LLC Attention: Zachary Prensky c/o Zackfoot Investments LLC, 382 Central Park West, New York, NY 10025. For any questions or comments regarding this press release, please contact us at For further information regarding the details of the share ownership mentioned above, please send a self-addressed stamped envelope to the IWB Acquisitions LLC address, also referenced above.

” Concentration is my motto – first honesty, then industry, then concentration. ” Andrew Carnegie